KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBITDA Margin (2017 - 2025)

Historic EBITDA Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 8.97%.

  • Amneal Pharmaceuticals' EBITDA Margin fell 36800.0% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 51900.0%. This contributed to the annual value of 8.92% for FY2024, which is 3900.0% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its EBITDA Margin stood at 8.97% for Q3 2025, which was down 36800.0% from 15.37% recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EBITDA Margin ranged from a high of 15.37% in Q2 2025 and a low of 35.51% during Q2 2022
  • In the last 5 years, Amneal Pharmaceuticals' EBITDA Margin had a median value of 8.97% in 2025 and averaged 6.33%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -480500bps in 2022, then soared by 488800bps in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' EBITDA Margin stood at 2.08% in 2021, then surged by 184bps to 5.91% in 2022, then tumbled by -61bps to 2.3% in 2023, then surged by 351bps to 10.38% in 2024, then dropped by -14bps to 8.97% in 2025.
  • Its last three reported values are 8.97% in Q3 2025, 15.37% for Q2 2025, and 14.43% during Q1 2025.